Form 4: Merit Medical Systems CEO Sells 10,000 Shares Under Pre-Arranged Plan

Fred P. Lampropoulos, President and CEO of Merit Medical Systems Inc. (MMSI), sold 10,000 shares of common stock for approximately $951,200, as disclosed in a recent SEC Form 4 filing.

Summary

• Fred P. Lampropoulos, the President and CEO of Merit Medical Systems Inc. (MMSI), reported the sale of 10,000 shares of the company's common stock.
• The transaction occurred on May 30, 2025, at a weighted average price of $95.12 per share, totaling approximately $951,200.
• The shares were sold in multiple transactions with prices ranging from $95.01 to $95.23.
• This sale was conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following this transaction, Mr. Lampropoulos directly beneficially owns 1,056,028 shares of common stock.
• Additionally, he has indirect beneficial ownership of 7,734.258 shares through his spouse, 97,892 shares through a 401(k) Plan, and 90 shares through his spouse as custodian for a child, though he disclaims beneficial ownership of shares held by his spouse.
• Mr. Lampropoulos also holds various non-qualified stock options with exercise prices ranging from $37.71 to $70.58, and expiration dates between March 1, 2026, and February 28, 2030, totaling 371,870 direct options and 2,000 indirect options through his spouse.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the CEO's sale of shares. While the sale was pre-planned under a 10b5-1 plan, which mitigates some of the negative implications, insider selling can still be perceived as a lack of strong conviction or a belief that the stock is fully valued. However, the CEO retains a substantial holding, preventing a strongly negative score.

Positives

• The sale was executed under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not a reaction to recent negative company developments.
• Despite the sale, the CEO retains a substantial direct beneficial ownership of 1,056,028 shares, demonstrating continued significant alignment with shareholder interests.
• The CEO also holds a considerable number of unexercised stock options, providing further incentive for long-term company performance.

Negatives

• The sale of 10,000 shares by the President and CEO, even if pre-planned, can be perceived by the market as a reduction in insider confidence or a signal that the stock is fully valued.
• The transaction reduces the CEO's direct equity stake in the company.

Risks

• Market perception of insider selling could lead to negative sentiment or downward pressure on the stock price, regardless of the reason for the sale.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is an insider transaction report and does not provide information on broader industry trends or competitive landscape. It reflects an individual executive's stock activity within the medical devices industry.

Stakeholder Impact

• Shareholders may interpret the CEO's share sale as a signal regarding the company's future prospects or valuation, potentially influencing their investment decisions.
• The transaction reduces the CEO's direct equity alignment with shareholders, though significant holdings remain.

Key Dates

Recommendation

Keywords

Merit Medical Systems, MMSI, Fred P. Lampropoulos, Insider Trading, SEC Form 4, Stock Sale, CEO, 10b5-1 Plan, Beneficial Ownership, Stock Options